Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Efficacy, predictability and safety in myopic LASIK with the FEMTO LDV Z6 Femtosecond and WaveLight EX500 Excimer laser platform

Poster Details

First Author: R.Murphy IRELAND

Co Author(s): B. Power   A. Leccisotti   M. O'Keefe   M. Guerin           

Abstract Details


To evaluate the 1-year visual and refractive outcomes of laser in situ keratomileusis (LASIK) performed using the combined Ziemer Z6 femtosecond and EX500 Alcon excimer Laser platform in eyes with myopic astigmatism.


Department of Refractive Surgery, Mater Private Hospital, Dublin, Ireland.


Retrospective analysis of 114 myopic LASIK procedures (59 patients) using the FEMTO LDV Z6 (Ziemer Ophthalmic Systems, Port, Switzerland) femtosecond laser and the Wavelight EX500 (Alcon Laboratories, Ft Worth, TX, USA) excimer laser. Inclusion criteria were preoperative spherical equivalent refraction (SEQ) up to -9.00 diopters (D), cylinder up to 6.00 D, and corrected distance visual acuity (CDVA) of 20/32 or better, with 12-months of refractive follow up. Standard outcomes analysis was performed.


At 1 year, 96% of eyes achieved a postoperative UDVA of 20/20 or better. No eyes lost 2 or more lines CDVA. Preoperative mean SEQ was -3.81 ± 1.92 D (range: -0.63 to -9.00 D) and mean cylinder -0.83 ± 0.87 D (range: 0.00 to -6.00 D). Postoperative mean SEQ was -0.10 D ± 0.38 after 1 year. SEQ was unchanged within 0.50 D in 97% eyes between months 3 and 12. Postoperative SEQ within 0.50 D of the intended target was seen in 82% of eyes, and within 1.00 D in 98%.


Standard outcome analysis in myopic LASIK using the combined FEMTO LDV Z6 and the EX500 excimer laser demonstrates excellent measures of efficacy, predictability and safety with minimal myopic regression at 1 year. These results reflect the increasing ability to meet patient expectations of freedom from spectacles without a compromise in visual quality.

Financial Disclosure:


Back to Poster listing